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Extensive studies in rodents with melanin-concentrating hormone (MCH) have demon-
strated that the neuropeptide hormone is a potent orexigen. Acutely, MCH causes an
increase in food intake, while chronically it leads to increased weight gain, primarily as an
increase in fat mass. Multiple knockout mice models have confirmed the importance of
MCH in modulating energy homeostasis. Animals lacking MCH, MCH-containing neurons,
or the MCH receptor all are resistant to diet-induced obesity. These genetic and pharma-
cologic studies have prompted a large effort to identify potent and selective MCH receptor
antagonists, initially as tool compounds to probe pharmacology in models of obesity, with
an ultimate goal to identify novel anti-obesity drugs. In animal models, MCH antagonists
have consistently shown efficacy in reducing food intake acutely and inhibiting body-weight
gain when given chronically. Five compounds have proceeded into clinical testing. Although
they were reported as well-tolerated, none has advanced to long-term efficacy and safety
studies.
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INTRODUCTION
The mammalian form of melanin-concentrating hormone
(MCH), is a 19-amino acid cyclic peptide encoded within a 165-
amino acid preprohormone (Figure 1) (Vaughan et al., 1989).
MCH has been associated with a wide variety of behaviors (see
recent reviews by Saito and Nagasaki, 2008; Antal-Zimanyi and
Khawaja, 2009; Chung et al., 2011), but the focus of this review is
the role of MCH in energy homeostasis. The amino acid sequence
of MCH is identical in all mammals evaluated and alternative
processing of the preproMCH peptide can generate two addi-
tional putative peptides, designated neuropeptide E-I (NEI) and
neuropeptide G-E (NGE) (Nahon et al., 1989). Several in vivo
studies have shown that MCH plays a role in a variety of physio-
logic processes mediated within the central nervous system (CNS),
including energy homeostasis sleep and arousal, and emotionality
(Yumiko and Nagasaki, 2008; Torterolo et al., 2009). Although less
studied, MCH may also have a role in peripheral tissues such as
in gut and pancreatic islet function (Pissios et al., 2007; Kokkotou
et al., 2008).
Two MCH G-protein coupled receptors (GPCRs) have been
characterized (Pissios et al., 2006; Chung et al., 2011). MCHR1
is found in all vertebrates, while MCHR2 is found in non-rodent
higher species, including primates (Hill et al., 2001; Sailer et al.,
2001).
Neurobiology, rodent genetics,and rodent pharmacologic stud-
ies all demonstrate that MCH and the MCH receptors are
involved in regulating body weight (Gomori et al., 2003, 2007;
Hervieu, 2006; Bednarek, 2007; Antal-Zimanyi and Khawaja, 2009;
Johansson, 2011; Cheon, 2012). On the basis of this informa-
tion, many pharmaceutical companies have pursued the devel-
opment of MCHR1 antagonists for the treatment of obesity (for a
recent review, see Johansson, 2011). Unfortunately, although a few
MCHR1 antagonists have entered development, no compound has
successfully demonstrated anti-obesity efficacy in a clinical trial.
It remains unclear if this lack of clinical efficacy is due to a lack
of efficacy via the MCH1R pathway or to the inability of teams to
identify safe and well-tolerated compounds with sufficient potency
and pharmacodynamics properties to test the hypothesis. This
review summarizes the evidence for a role of MCH and its recep-
tors in energy homeostasis and the progress made to date toward
identifying small-molecule antagonists to treat obesity.
MCH ACTS THROUGH TWO G-PROTEIN COUPLED
RECEPTORS
Originally described as the orphan receptor SLC-1/GPR24
(Kolakowski et al., 1996), MCHR1 was later shown by five groups
to be activated by MCH (Pissios et al., 2006). The 402-amino
acid rodent and human MCHR1 receptors are highly homolo-
gous, sharing ∼95% identity (Pissios and Maratos-Flier, 2003),
and the highest expression of the receptors is within the brain
(Saito et al., 1999; Hill et al., 2001). Like many family A GPCRs,
the MCHR1 receptors have consensus N -glycosylation sites at the
amino terminus and several potential phosphorylation sites in the
intracellular loops (Lakaye et al., 1998).
In recombinant cell lines, the natural ligand, MCH, binds to
MCHR1 with ∼1 nM affinity, and it couples to Gi, Go, and Gq
proteins (Hawes et al., 2000; Pissios et al., 2003). Thus, activation
of MCHR1 leads to an increase in intracellular Ca++ accumulation
acting through the Gq-coupled pathway and/or to lowered cyclic
adenosine monophosphate (cAMP) levels via the Gi/o-coupled
pathway. Further analyses of the signaling of MCHR1 in recombi-
nant cell lines and in brain slices demonstrates that activation of
MCHR1 also leads to ERK phosphorylation (Pissios et al., 2003). In
3T3-L1 adipocytes, MCH rapidly induced a threefold to fivefold
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FIGURE 1 |The amino acid structure of mammalian MCH.
increase in MAPK pathway activities (Bradley et al., 2002). It is
unclear if all, or some, of these signaling pathways contribute to
MCH-mediated events in vivo.
A second MCHR was later identified and termed MCHR2 by
six groups (Antal-Zimanyi and Khawaja, 2009). The functional
role of MCHR2 is not well defined, in part because it is not
expressed in rodents and related species (hamsters, guinea pigs,
or rabbits), but it is expressed in humans, dogs, ferrets, and mon-
keys (Tan et al., 2002). The amino acid sequence identity between
MCHR1 and MCHR2 is low,∼38%, with the highest homology in
the seven-transmembrane domains that form the ligand binding
pocket (Sailer et al., 2001). Although MCH binds to MCHR1 and
MCHR2 with a similar nanomolar affinity, the signal transduction
mechanism of MCHR2 is limited to the Gq-mediated increase in
intracellular Ca++ levels (Sailer et al., 2001). MCHR2 is largely co-
expressed with MCHR1 in the CNS (Sailer et al., 2001), although
peripheral expression was also found in adipocytes, pancreas,
prostate, and intestine (An et al., 2001). The phylogenetic tree
of MCH-related receptors contains opioid, somatostatin, galanin,
urotensin 2, and orphan receptors (Sailer et al., 2001). MCH recep-
tors have the highest homology (about 40%) with the somatostatin
receptors (Sailer et al., 2001).
NEUROANATOMY OF MCH AND MCH RECEPTORS
Melanin-concentrating hormone has been implicated in many
behaviors. The hypothalamus is one of the primary sites in which
MCH-containing nerve fibers and MCH receptors are extensively
expressed (Gao, 2009). Although most of the MCH neurons are
located within the incerto-hypothalamic and lateral hypothalamic
area (LHA), a recent review by Bittencourt details the locations
throughout the brain of MCH nerve terminals (Bittencourt, 2011).
Neural signaling by MCH via its receptors has been implicated in
the control of energy balance, but due to the wide distribution
of MCH-containing fibers throughout the brain, the critical sites
of action for particular behaviors have not been identified (Zheng
et al., 2005). In male rats,neurons expressing MCH are found in the
LHA and medial zona incerta, as well as, sparsely, in the olfactory
tubercle and pontine reticular formation. The wide distribution
of MCH fibers suggests the involvement of this neuropeptide in
a variety of functions, including arousal, neuroendocrine control,
and energy homeostasis (Rondini et al., 2007).
Melanin-concentrating hormone-expressing neurons in the
LHA play an integrative role between signals from the periph-
ery, acting via first-order neurons in the arcuate nucleus, and
then from extra-hypothalamic systems, which modulate regula-
tion of feeding, drinking, and seeking behaviors (Guyon et al.,
2009). Factors from the periphery affect brain activity, result-
ing in changes in food intake and energy expenditure. Neurons
from the arcuate nucleus detect changes in homeostatic parame-
ters and transmit information to other brain areas, including the
LHA. These secondary area neurons have widespread projections
throughout the brain, and their activation leads to coordinated and
altered behaviors (Guyon et al., 2009). About 25% of the LHA neu-
rons projecting to the pedunculopontine tegmental (PPT) nucleus
are immunoreactive for MCH, and 75% of the LHA neurons
projecting to the cerebral motor cortex also contain MCH (Elias
et al., 2008). Also, 15% of the incerto-hypothalamic neurons pro-
jecting to the PPT express MCH immunoreactivity. The MCH
neurons express glutamic acid decarboxylase mRNA, a gamma-
aminobutyric acid (GABA) synthesizing enzyme, indicating that
the MCH/GABA neurons are involved in inhibitory modulation
and their activation may lead to decreased motor activity in states
of negative energy balance (Elias et al., 2008). Like MCH, vaso-
pressin and oxytocin can influence energy homeostasis and other
behaviors. Whole-cell recording in hypothalamic brain slices from
the MCH-green fluorescent protein transgenic mouse revealed
that both vasopressin and oxytocin evoked a substantial excitatory
effect on MCH-expressing cells (Yao et al., 2012). Both neu-
ropeptides reversibly increased spike frequency and depolarized
the membrane potential in a concentration-dependent manner,
suggesting that vasopressin or oxytocin exerts a robust excitatory
effect on presumptive GABA cells that contain MCH (Yao et al.,
2012).
Interestingly, projections to ventral medullary sites apparently
play a role in the inhibitory effect of MCH on energy expenditure,
but not food intake (Zheng et al., 2005). In the rat, a signifi-
cant proportion (5–15%) of primarily perifornical and far-lateral
hypothalamic MCH neurons project to the dorsal vagal com-
plex. Retrograde tracing in the caudal brainstem demonstrated
that MCH-immunoreactive axons are distributed densely in the
nucleus of the solitary tract, in the dorsal motor nucleus of the
vagus, and in sympathetic premotor areas in the ventral medulla
(Zheng et al., 2005). In medulla slice preparations, MCH inhibited
the amplitude of excitatory postsynaptic currents. Administration
of MCH in the fourth ventricle in freely moving rats decreased
core body temperature, but it did not change locomotor activity
or food and water intake (Zheng et al., 2005).
The MCH pathways from the lateral hypothalamus to the mam-
millary nucleus may also enable the animal to look for food during
the initial moments of appetite stimulation (Casatti et al., 2002).
Injection of the retrograde tracer True Blue in the medial mam-
millary nucleus led to MCH/True Blue double-labeled neurons
in the LHA, the rostromedial zona incerta, and the dorsal tubero-
mammillary nucleus. The afferents were confirmed using implants
of the anterograde tracer Phaseolus vulgaris leucoagglutinin. The
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MCH projections may participate in spatial memory processing
mediated by the medial mammillary nucleus (Casatti et al., 2002).
In addition to the LHA, the nucleus accumbens shell (AcSh) is
a brain region important for food intake. The AcSh contains high
levels of receptor for MCH. MCH receptor activation in the AcSh
increases food intake, while AcSh MCH receptor blockade reduces
feeding. Moreover, in vivo recordings confirm that MCH reduces
neuronal activity in the AcSh in freely moving animals, consistent
with a model from other pharmacological and electrophysiological
studies whereby reduced AcSh neuronal firing leads to food intake
(Sears et al., 2010). Since the AcSh mediates reinforcing proper-
ties of food, MCH may modulate motivational aspects of feeding.
Indeed, chronic loss of rat MCH decreased food intake predom-
inantly via a reduction in meal size during development and
reduced high-fat food reinforced operant response in adult rats
(Mul et al., 2011). Also, chronic loss of ProMCH in the rat affects
the limbic dopamine system, since adult Pmch−/− rats showed
increased ex vivo electrically evoked dopamine release (Mul et al.,
2011). Thus, MCH actions in the AcSh mediate motivational
aspects of feeding behavior.
MCHR1 is widely distributed in the brain (Hervieu et al., 2000;
Able et al., 2009). Hervieu et al. (2000) used in situ hybridiza-
tion histochemistry and immunohistochemistry to determine that
Mchr1 mRNA and protein were widely expressed throughout the
rat brain. Similar to the distribution of MCH, Mchr1 signals were
observed in the cerebral cortex, caudate-putamen, hippocampal
formation, amygdala, hypothalamus, and thalamus, as well as
in various nuclei of the mesencephalon and rhombencephalon
(Hervieu et al., 2000). Able et al. (2009) used an MCHR1-specific
radioligand to demonstrate highly MCHR1-specific binding in the
rat nucleus accumbens, caudate-putamen, and preform cortex, as
well as lower levels of binding in the hippocampus and amygdala.
Surprisingly, and in contrast to Hervieu et al. (2000) and Able et al.
(2009) did not detect MCHR1 binding in the hypothalamus.
The distribution of MCHR2 in the primate brain nearly
overlaps that of MCHR1, but the latter shows much higher
relative levels and a wider distribution pattern (Mori et al.,
2001). MCHR2 is expressed in several human brain areas,
including the hippocampus and amygdala, although its dis-
tribution in the hypothalamus remains controversial. Specifi-
cally, MCHR2 mRNA was reported to be mainly expressed in
the arcuate nucleus and ventromedial hypothalamic nucleus in
African green monkeys by in situ hybridization (Sailer et al.,
2001), while three other reports did not detect its expression
in the human hypothalamus by RT-PCR (Hill et al., 2001;
Mori et al., 2001) or Northern blot analysis (Rodriguez et al.,
2001).
HUMAN GENETICS OF MCH AND ENERGY HOMEOSTASIS
Genetic analysis of obese subjects has identified several variants
of MCH and the MCH receptors, but no alterations have been
conclusively linked to obesity or leanness. In an association study,
among 106 subjects with severe early onset obesity and a history
of hyperphagia, two missense variants were found in MCHR1:
Y181H and R248Q (Gibson et al., 2004). Neither of these was
found in 192 normal-weight controls. R248Q co-segregated with
obesity across two generations,but family data were unavailable for
Y181H. When tested for functional response, the R248Q variant
showed no evidence of constitutive activation, alteration in cAMP
signaling, or ligand hypersensitivity (Gibson et al., 2004). Two
common single-nucleotide polymorphisms (SNPs) were found to
be in linkage disequilibrium, but no association between either of
these and obesity-related phenotypes was found among a popula-
tion cohort of 541 whites. Only two rare, non-coding variants were
found inMCHR2. However, the relationship of theseMCHR2 vari-
ants to metabolic phenotypes has not been clarified (Gibson et al.,
2004). Genomic screening of 13.4 kb encompassing the MCHR1
in extremely obese German children and adolescents identified
11 infrequent variations and two SNPs in the MCHR1 coding
sequence and 18 SNPs (eight were novel) in the flanking sequence.
Although an association of an MCHR1 haplotype (SNPs rs133072
and rs133073) with obesity was observed in two cohorts of German
children and adolescents, it was not confirmed in five indepen-
dent cohorts (Wermter et al., 2005). To investigate the possible
polygenic role of MCHR1, six common SNPs (minor allele fre-
quency>5%) found in the sequenced regions were screened in 557
morbidly obese adults, 552 obese children, and 1195 non-obese
non-diabetic control subjects (Bell et al., 2005). The plausible pro-
moter SNP, rs133068, was found to be associated with protection
against obesity in obese children only (Bell et al., 2005).
A functional analysis of 11 MCHR1 variants that had been
reported previously in the literature identified two mutant recep-
tors, R210H and P377S, that failed to respond to MCH (Goldstein
et al., 2010). Five other variants showed significant alterations in
MCH efficacy, ranging from 44 to 142% of the wild-type value.
Both inactive receptors had cell surface expression that was compa-
rable to wild-type (Goldstein et al., 2010). It is of note that the two
loss-of-function mutants were identified in markedly underweight
individuals, raising the possibility that a lean phenotype may be
linked to deficient MCHR1 signaling (Goldstein et al., 2010). Addi-
tional association studies with larger cohorts are needed to explore
the extent to which signaling-deficient MCHR1 variants influence
the maintenance of body weight.
The association between MCHR2 variation and human obesity
was investigated in 141 obese children and 24 non-obese adult
subjects by DNA sequencing, and by case-control analyses using
628 severely obese children and 1401 controls (Ghoussaini et al.,
2007). None of the MCHR2 variants showed an association with
adult severe obesity, but the A76A SNP was associated with severe
obesity (P = 0.01) and overeating in obese children (P = 0.02)
(Ghoussaini et al., 2007). Validation of an association of MCHR2
with obesity requires replication in other cohorts.
The common allele of the ProMCH gene, rs7973796, may
be associated with a higher body mass index (BMI) in
olanzapine-treated patients with schizophrenia. In a subgroup
of subjects under 50 years of age among 300 schizophrenia
patients, the rs7973796 genotype was associated with an effect
on BMI among patients taking olanzapine (interaction P = 0.025)
(Chagnon et al., 2007). Olanzapine-treated patients with schizo-
phrenia carrying the homozygote genotype showed a higher BMI
for rs7973796 (P = 0.016 with the least-squares means t -test) than
the variant homozygotes. The G allele was associated with an
increase in the odds of obesity in schizophrenic patients taking
olanzapine (Chagnon et al., 2007).
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RODENT GENETICS INDICATE A ROLE FOR MCH IN ENERGY
HOMEOSTASIS
Multiple mouse knockout (KO) models have been constructed to
explore the role of MCH in energy homeostasis and other MCH-
mediated behaviors. The KO models include multiple constructs
that prevent synthesis of MCH and the MCHR1 receptor. Studies
of these mice show that loss of MCH function leads to leanness
and resistance to obesity.
MCH KO MICE
Strong evidence that MCH mediates energy homeostasis came
from studies of mice in which the Promch gene was inactivated.
Mice constructed with targeted inactivation of the Promch gene
in a mixed C57BL/6× 129SvJ genetic background had reduced
body weight and leanness due to hypophagia (reduced feeding)
and an increased metabolic rate, despite reduced amounts of both
leptin and arcuate nucleus proopiomelanocortin mRNA (Shi-
mada et al., 1998). Evaluation of Promch inactivation in pure
genetic backgrounds confirmed that Promch deficiency increased
energy expenditure and promoted increased running-wheel activ-
ity (Kokkotou et al., 2005; Zhou et al., 2005). As observed previ-
ously on a mixed background, the C57BL/6 Promch KO mice were
hypophagic; however, the 129SvEv Promch KOs were hyperphagic,
relative to wild-type. In both C57BL/6 and 129SvEv backgrounds,
deletion of Promch led to reduced adiposity, attenuated weight
gain, and increased locomotor activity, compared with wild-type
counterparts. The relative increase in activity was greater on a
high-fat diet (HFD) than on regular chow (Kokkotou et al., 2005).
The lean phenotype of the Promch KO mice persisted as the mice
aged. At 19 months, C57BL/6 Promch−/− male and female mice
weighed about 25% less than their wild-type counterparts as a
result of reduced fat mass inPromch−/−mice. The agedPromch−/−
mice exhibited improved glucose tolerance in intraperitoneal glu-
cose tolerance tests, were more insulin sensitive, and were more
active compared with wild-type controls (Jeon et al., 2006).
Further confirmation of the role of MCH in energy homeosta-
sis came from studies of Promch neuron-ablated mice, generated
using toxin (ataxin-3)-mediated ablation strategy in an FVB/n
background (Alon and Friedman, 2006). In these mice, the Promch
gene is present throughout development, but 60–70% of MCH-
expressing neurons degenerate in the first few weeks of life (Alon
and Friedman, 2006). After 7 weeks of age, the mice developed
reduced body weight, body length, fat mass, lean mass, and lep-
tin levels. As observed in the C57BL/6 Promch−/− mice, leanness
was characterized by hypophagia and increased energy expen-
diture. In leptin-deficient ob/ob mice, loss of either Promch or
MCH-containing neurons improved obesity, diabetes, and hepatic
steatosis, suggesting that MCH is an important mediator of the
response to leptin deficiency (Segal-Lieberman et al., 2003; Alon
and Friedman, 2006).
Promch tg MICE
The phenotype of Promch tg mice overexpressing MCH also sup-
ports a role for MCH in energy homeostasis. Ludwig et al. (2001)
constructed transgenic mice that overexpressed Promch in the lat-
eral hypothalamus at ∼twofold higher levels than normal mice.
On an FVB background, the homozygous transgenic mice fed a
HFD ate 10% more and were 12% heavier than wild-type ani-
mals. Blood glucose levels were higher both preprandially and
after an intraperitoneal glucose injection, and the transgenic mice
were insulin-resistant (Ludwig et al., 2001). Promch tg heterozy-
gous mice on a C57Bl/6 background were hyperphagic on regular
chow, heavier, and insulin-resistant, but did not have elevated
blood glucose (Ludwig et al., 2001).
Mchr1−/− MICE
As the gene for preproMCH encodes two additional peptides, NEI
and NGE of unknown function (Nahon et al., 1989), studies with
Mchr1KO mice provided clarification and confirmation of the role
of MCH in energy homeostasis. Three groups independently pro-
duced Mchr1−/− mice. Chen et al. (2002) reported that Mchr1 KO
mice on a C57BL/6× 129SvJ mixed background were resistant to
diet-induced obesity and had fat mass that was significantly lower
in both male (4.7± 0.6 vs. 9.6± 1.2 g) and female (3.9± 0.2 vs.
5.8± 0.5 g) mice than that of the wild-type control. The mice were
hyperphagic on a HFD, but had a 28% higher metabolic rate than
wild-type. Both leptin and insulin levels were significantly lower in
maleMchr1−/−mice than in the wild-type controls, but there were
no detectable differences in glucose levels. No differences were
observed between heterozygotes and wild-type mice (Chen et al.,
2002). Marsh et al. (2002) observed that Mchr1−/− mice also con-
structed on a C57BL/6× 129SvJ mixed background had normal
body weights, yet they had reduced fat mass and were hyperphagic
when maintained on regular chow. In agreement with Chen et al.
(2002) they observed that Mchr1−/− mice were less susceptible to
diet-induced obesity, and the KO leanness was a consequence of
hyperactivity and altered metabolism (Marsh et al., 2002). A later
study by Zhou et al. (2005) showed that the Mchr1 KO mice had
a dramatic 250% increase in running-wheel activity along with
hyperphagia (Antal-Zimanyi and Khawaja, 2009). Astrand et al.
(2004) also independently generated Mchr1−/− mice on a mixed
C57BL/6× 129SvJ background and observed that the mice had an
elevated metabolic rate and were hyperactive, hyperphagic, and
lean. A >12% increase in heart rate without any change in blood
pressure was noted (Astrand et al., 2004). Two groups studied
Mchr1 KO mice after backcrossing onto a C57BL/6 background
(Bjursell et al., 2006; Ahnaou et al., 2011). In leptin-deficient ob/ob
mice, loss of Mchr1 reduced adiposity (although body weights
were not statistically different), improved the response in an oral
glucose tolerance test (OGTT), increased spontaneous movement,
and improved thermoregulation upon exposure to cold, suggest-
ing that MCH is an important mediator of the response to leptin
deficiency (Bjursell et al., 2006).
The role of MCHR2 has not been investigated in animal mod-
els. MCHR2 is absent in rodents but is present in higher species,
including primates (Hill et al., 2001; Sailer et al., 2001). The role
of MCHR2 might be studied in MCHR2-humanized mice, but
no such model has been described. Alternatively, in vivo studies
with MCHR1- and MCHR2-selective agonists could be used to
study the role of MCHR2 in non-rodent species with a functional
MCHR2. Indeed, it is surprising that in vivo pharmacological stud-
ies with selective ligands have not been performed, in light of the
availability of MCH peptides that are potent dual MCHR1/R2 ago-
nists, selective MCHR1 agonists, MCHR2-preferring agonists, and
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Table 1 | Mouse genetic models supporting a role for MCH in energy homeostasis.
Genotype Phenotype Reference
Promch−/−C57BL/6×129SvJ Hypophagic, reduced adiposity, increased metabolic rate, and reduced
weight
Shimada et al. (1998)
Promch−/− C57BL/6 Normophagic, reduced adiposity, increased activity and metabolic rate,
and reduced weight
Zhou et al. (2005), Kokkotou et al. (2005)
Promch−/−C57BL/6×129SvEv Hyperphagic, reduced adiposity, increased activity and metabolic rate,
and reduced weight
Kokkotou et al. (2005)
Promch;ataxin-3 FVB/n Hypophagic, reduced adiposity, increased metabolic rate, normo-activity,
and reduced weight
Alon and Friedman (2006)
Promch;ataxin-3;ob/ob
(FVB/nXC57BL/6)
Hyperphagic, reduced adiposity, reduced glucose, reduced steatosis,
and reduced weight
Alon and Friedman (2006)
Promch−/−;ob/ob C57BL/6 Reduced adiposity, reduced glucose, increased metabolic rate,
increased activity, and reduced weight
Segal-Lieberman et al. (2003)
Promch tg/tg FVB Increased weight, hyperphagic on HFD, increased glucose, and
insulin-resistant
Ludwig et al. (2001)
Promch tg/+ C57BL/6 Increased weight, hyperphagic on chow, normo-glucose, and
insulin-resistant
Ludwig et al. (2001)
Mchr1−/− C57BL/6×129SvJ Reduced adiposity, hyperphagic, hyperactive, reduced weight, higher
metabolic rate, and reduced insulin
Marsh et al. (2002), Chen et al. (2002),
Astrand et al. (2004), Zhou et al. (2005)
Mchr1−/+ C57BL/6×129SvJ No differences vs. wild-type Chen et al. (2002)
Mchr1−/− C57BL/6 Reduced insulin, improved OGTT, and elevated body temperature Bjursell et al. (2006), Ahnaou et al. (2011)
Mchr1−/−;ob/ob C57BL/6 Decreased adiposity, reduced insulin, improved OGTT, increased activity Bjursell et al. (2006)
potent MCHR1/R2 antagonists (MacNeil and Bednarek, 2009). At
this point, it is unclear if MCHR1 and MCHR2 play redundant or
unique roles in MCH signaling in primates, or whether MCHR2
plays any significant role in energy homeostasis in humans.
Multiple mouse models show that disruption of the MCH sys-
tem, via either the peptide ligand or the receptor, results in altered
energy homeostasis (Table 1). In general, loss of MCH signaling
leads to a lean, diet-induced obese (DIO)-resistant phenotype due
primarily to increased energy expenditure, and in some models,
lower food intake.
PHARMACOLOGIC STUDIES CONFIRM A ROLE FOR MCH IN
ENERGY HOMEOSTASIS
In vivo studies have shown that MCH or MCH analogs
increase food intake and body weight, while, conversely, studies
with MCHR1 antagonists reduce body weight and associated
comorbidities.
IN VIVO EFFECTS OF MCH PEPTIDE AGONISTS
Melanin-concentrating hormone, and occasionally MCH deriv-
atives, have been used to evaluate the role of MCH in energy
homeostasis. Most studies have utilized acute injections of MCH
into either specific brain nuclei or, more commonly, the third
or fourth ventricle. These injections almost certainly lead to
supraphysiologic levels of MCH in at least some of the MCH
receptor-containing nuclei. Qu et al. (1996) were the first to show
that intracerebroventricular (ICV) MCH increased food intake. In
multiple experiments ICV injections of 5 or 30µg into Long Evans
rats increased 2-, 4-, and 6-h food intake between 150 and 200%
(Qu et al., 1996). ICV injection of MCH into the third ventricle
of either Wistar or Sprague-Dawley rats also increased food intake
(Qu et al., 1996; Della-Zuana et al., 2002; Shearman et al., 2003).
The orexigenic effects of ICV MCH were maximal at 2 h post injec-
tion (Della-Zuana et al., 2002). In Wistar rats, low doses (0.1 and
0.5µg/rat) were ineffective, while higher doses (1, 5, and 10µg/rat)
were equally effective, leading to an approximate doubling of food
intake over 2–4 h (Della-Zuana et al., 2002). In Sprague-Dawley
rats, only the two highest doses led to significant increases in food
intake (Della-Zuana et al., 2002). When presented with sucrose
solutions after ICV injection of MCH (2 nmol), Sprague-Dawley
rats increased their intake of sucrose solution by increasing the rate
of licking (Baird et al., 2006). The role of MCH in energy home-
ostasis was also confirmed in sheep, which have both MCHR1 and
MCHR2; acute ICV doses of MCH increased food intake (Whit-
lock et al., 2005). Potent MCH analogs (IC50 < 25 nM), but not
the weak analogs (IC50 > 1000 nM), reduced 2-h food intake after
ICV administration of 4.4 nmol to Wistar rats (Suply et al., 2001).
In a separate study in Sprague-Dawley rats using a smaller, potent
MCH analog, Shearman et al. (2003) observed dose-dependent
increases in 6-h food intake after an ICV injection of an MCH
agonist (1µg/rat, +68%; 5µg/rat, +76%; 15µg/rat, +122%).
Guesdon et al. (2008) confirmed that the smaller MCH analog,
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when given ICV at 5µg/rat, increased food intake in Wistar rats
threefold over a 2-h period.
Intracerebroventricular injection of MCH into the third ven-
tricle of rats significantly increased the ingestion of sucrose and
glucose solution, but not of saccharin, indicating that the MCH-
induced dipsogenic response is more related to caloric content
than to sweet taste per se (Sakamaki et al., 2005). Injections of
MCH into several brain nuclei led to increases in food intake.
MCH (0.6 nmol) elicited a rapid and significant increase in feed-
ing in satiated rats following injection into the arcuate nucleus, the
paraventricular nucleus, or the dorsomedial nucleus (Abbott et al.,
2003). However, no significant alteration in feeding was observed
following injection into other brain regions associated with energy
homeostasis, including the supraoptic nucleus, LHA, medial pre-
optic area, anterior hypothalamic area, or ventromedial nucleus of
the hypothalamus (Abbott et al., 2003).
In a side-by-side comparison, MCH was found to be a weaker
orexigen than two other hypothalamic neuropeptides. In lean rats,
1 and 3 nmol of the ICV-injected orexigenic peptides, neuropep-
tide Y (NPY) and agouti-related protein (AGRP), showed robust
increases in intake of a sucrose solution, but 3 nmol of MCH
mediated only a non-significant trend toward increased feeding
(Semjonous et al., 2009). The importance of forebrain hypothal-
amic regions for MCH action was apparent when injection of
6 nmol of MCH into the fourth ventricle of lean rats or sheep failed
to induce increased food intake, while control injections of NPY
did increase food intake (Whitlock et al., 2005; Baird et al., 2007).
Administration of LiCl, a potent inducer of conditioned taste aver-
sion (CTA), to rats leads to an upregulation of Mch and Mchr1
mRNA (Mitra et al., 2012). However, when MCH was injected
prior to the induction of CTA with LiCl, as well as later during the
CTA retrieval, MCH treatment did not reduce the magnitude of
CTA upon subsequent presentations of the aversive tastant (Mitra
et al., 2012). Thus, MCH is not critical to the development of CTA.
Although most ICV studies leading to an increase in food intake
utilized injection into the third ventricle, Georgescu et al. (2005)
demonstrated that direct injection of 1µg of MCH into the AcSh,
a region rich in MCHR1, resulted in a robust increase in food
intake by Sprague-Dawley rats lasting at least 4 h. Guesdon et al.
(2008) used a potent, truncated MCH analog and also observed
that injection of 5µg into the AcSh of Wistar rats increased food
intake of regular chow threefold during the 2 h following injection.
Agonist studies in preproMCH-deficient rats confirmed that
the orexigenic actions of MCH are independent of two other
preproMCH encoded peptides, NGE and NEI. Acute AcSh admin-
istration of NGE and NEI, or chronic ICV infusion of NEI, did
not affect feeding behavior in adult Promch+/+ or Promch−/− rats
(Mul et al., 2011). However, acute administration of MCH to the
AcSh of adult Promch−/− rats elevated feeding behavior toward
wild-type levels (Mul et al., 2011).
In addition to the effects of MCH on food intake, the role
of MCH in mediating energy expenditure was also compared
with that of two other orexigenic peptides, AGRP and orexin.
Both AGRP and orexin, administered ICV (1 nmol/mouse), sig-
nificantly decreased oxygen consumption compared with arti-
ficial cerebrospinal fluid (aCSF) treated controls; in contrast,
MCH (1 nmol/mouse) had no significant effect compared with
aCSF-treated controls (Asakawa et al., 2002). However, an effect
of MCH on oxygen consumption might not have been detected,
since only a relatively low dose of peptide was tested.
Chronic ICV infusions of MCH into rodents were shown to
not only increase food intake, but to also cause obesity (Della-
Zuana et al., 2002; Gomori et al., 2003; Ito et al., 2003); while
MCH-induced insulin resistance in rats was observed acutely in the
absence of weight changes (Pereira-da-Silva et al., 2005). Chronic
infusions of MCH (8µg/rat/day) over 12 days led to an increase
in body weight of about 20 g more than did control aCSF infu-
sions in both Wistar or Sprague-Dawley rats (Della-Zuana et al.,
2002). After a 14-day infusion of MCH into the third ventricle
of C57BL/6J mice (10µg/day), no significant increase in food
intake was observed in mice fed a regular chow, but on a mod-
erately high-fat diet (MHF), the mice ate about 15% more food
(Gomori et al., 2003). Mice on both diets were significantly heav-
ier than control mice, with the largest increase in body weight
observed in the MCH infused mice on a MHF diet; these mice
gained 17% more weight than the control infused mice on an MHF
diet (Gomori et al., 2003). Glick et al. (2009) also observed that
chronic infusion of 10µg/day of MCH for 14 days into C57BL/6
mice fed regular chow led to a 34% increase in food intake and
a 15% increase in body weight after a 14-day infusion. In a sepa-
rate study, C57BL/6J mice on an MHF diet infused with a lower
amount of MCH (3µg/day for 7 days) also were hyperphagic and
gained 350% more weight than did the vehicle control mice, with
no detectable changes in activity (Ito et al., 2003). In addition,
a small, potent, MCH analog given chronically ICV (30µg/day)
to Sprague-Dawley rats increased food intake by 23% and body
weight by 38% more than in the vehicle controls (Shearman et al.,
2003).
Intracerebroventricular-injected MCH has metabolic effects
beyond increases in food intake and body weight. The acute
effects of single MCH injections probably identify direct effects
from increased MCH signaling in the brain, while the chronic
effects may be subsequent to increased adiposity associated with
body-weight gain. A single ICV injection of MCH into Wistar
rats (3 nmol) inhibited the thyroid axis (Kennedy et al., 2001)
by suppressing release of thyroid hormone from the hypothal-
amus, leading to a suppression of plasma thyroid-stimulating
hormone (Kennedy et al., 2001). ICV injections of 4 nmol of MCH
into Wistar rats for 4 days resulted in an ∼10% increase in fast-
ing plasma glucose (Pereira-da-Silva et al., 2005). Guesdon et al.
(2008) used a potent, truncated MCH analog and found that injec-
tion of 5µg into the AcSh or the third ventricle of Wistar rats did
not significantly increase energy expenditure, but it did increase
glucose oxidation and reduce lipid oxidation in the period 3 h after
injection.
Chronic ICV infusions of MCH into C57BL/6J mice resulted
in increased fat pad weights (∼100%), leptin (∼300%), liver
triglycerides (∼120%), fasting plasma glucose (∼10%), and
insulin (∼100%) (Gomori et al., 2003). Glick et al. (2009)
also observed that chronic infusion of 10µg/day of MCH for
14 days into C57BL/6 mice led to a 4.5-fold increase in adipos-
ity, about a 0.4˚C drop in body temperature during the active
dark phase, a 15% decrease in oxygen utilization, and a 26%
increase in plasma insulin-like growth factor 1 levels. Chronic
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MCH agonist infusions into Sprague-Dawley rats also led to
increases in insulin (∼200%) and leptin (∼400%) (Shearman
et al., 2003).
IN VIVO EFFECTS OF MCH RECEPTOR ANTAGONISTS
As discussed above, rodent genetic models clearly show a role for
MCH in energy homeostasis. However, the applicability of these
studies to understanding the physiological role and disease states
associated with MCH signaling may be limited due to develop-
mental effects of MCH inactivation or neuronal loss affecting
other neuromodulators. Moreover, the relevance of in vivo phar-
macology studies is complicated, because they utilize MCH and
MCH agonists administered ICV at what are probably supraphys-
iologic levels. To better understand the role of MCH in energy
homeostasis, a series of in vivo studies utilized MCHR1-specific
antagonists. Because many pathways can affect food intake and
body weight, in vivo effects of MCHR1 antagonists might be due
to non-specific effects; however, in a few cases, researchers have
demonstrated MCHR1 specificity by showing that an antagonist
is inactive in Mchr1−/− mice.
Studies with MCHR1 peptidic antagonists
Studies on truncated and substituted MCH analogs identified
key amino acids for activation of the MCH receptors and led
to synthesis of potent antagonist derivatives (Bednarek et al.,
2002; Audinot et al., 2009). Several in vivo studies employed Ac-
(Ava9–10, Ava14–15)-MCH(6–16)-NH2, a truncated, cyclic MCH
analog containing γ-aminovaleric acid which is a potent (Kb
4 nM) antagonist (MacNeil and Bednarek, 2009). Shearman et al.
(2003) reported that the peptide antagonist given ICV (10µg) did
not significantly reduce spontaneous feeding, affect feeding dura-
tion or locomotor activity, or alter overnight body-weight gain
in lean male Sprague-Dawley rats. However, the peptide antago-
nist blocked the initial 2- or 3-h hyperphagic activity of an MCH
agonist (Shearman et al., 2003; Mashiko et al., 2005). Chronic
ICV infusion of the antagonist at 48µg/day for 14 days reduced
cumulative food intake by 13% and body-weight gain by 33%, rel-
ative to vehicle controls (Shearman et al., 2003). In male C57BL/6J
mice fed an MHF diet, 28-day ICV infusion of the peptide antag-
onist at 7.5µg/day decreased cumulative food intake 15% and
the antagonist-treated mice weighed 13% less than the vehicle-
infused controls (Mashiko et al., 2005). The antagonist treatment
led to improvements in other metabolic parameters, including
reductions in plasma glucose, leptin, insulin, and total choles-
terol, as well as reductions in fat pad and liver weights (Mashiko
et al., 2005). The specificity of the MCHR1 peptide antagonist was
confirmed using Mchr1−/− mice, as infusion of the antagonist for
2 weeks had no effect on body weight, fat mass, or cumulative food
intake in the KO mice (Mashiko et al., 2005). In contrast to Mchr1
KO mouse models (Table 1), no changes were noted in activ-
ity after a 4-week infusion of the MCHR1 antagonist (Mashiko
et al., 2005). Obese, aged, male C57BL/6J mice fed a HFD for
1 y (body weight ∼60 g) were subjected to a 4-week ICV infusion
with the peptide antagonist at 7.5µg/day (Ito et al., 2008). The
antagonist-infused mice lost 21% of their weight, while vehicle-
infused mice gained 6% more weight. Not surprisingly, given the
large differences in body weight, the MCHR1 antagonist-treated
mice showed significant reductions in serum leptin and insulin
(Ito et al., 2008). Also, the liver weights of the antagonist-treated
DIO mice decreased by about 50%, while the serum liver markers
showed improvements (Ito et al., 2008). In a follow-up study to
explore the role of MCH in modulating accumulation of triglyc-
erides in liver, male C57BL/6J mice were fed a diet deficient in
methionine and choline to induce steatohepatitis; ICV treatment
with the MCHR1 antagonist (7.5µg/day for 10 days) did not result
in any body-weight difference vs. vehicle control, but accumula-
tion of triglycerides in liver was reduced 33% (Ito et al., 2008).
The ability of MCHR1 antagonist treatment to improve hepatic
steatosis was confirmed in a female model of obesity in which
ovariectomized mice were fed a regular chow diet. Thirty weeks
after the ovariectomy, the female C57BL/6J mice weighed about
25% more than did the sham treated mice (Gomori et al., 2007).
When these obese mice were treated ICV with the MCHR1 pep-
tide antagonist for 4 weeks at 7.5µg/day, they lost 13% of their
body weight and 32% of their liver triglycerides (Gomori et al.,
2007).
Studies with S38151 in multiple rodent models of obesity
resulted in significant effects on food intake and body weight.
S38151 [p-guanidinobenzoyl-[des-Gly10]-MCH(7–17)] is a mod-
ified and truncated 11-amino acid MCH analog which is a potent
(Kb= 4 nM) MCHR1 antagonist (Audinot et al., 2009). Injec-
tion of this peptidic MCHR1 antagonist into the AcSh reduced
food intake (Georgescu et al., 2005). Over a 6-h period, in male
Wistar rats, S38151 administered ICV dose dependently inhib-
ited the orexigenic effects of previously injected MCH (Audinot
et al., 2009). The highest doses of S38151, 30 and 50 nmol per rat,
completely blocked MCH-induced food intake for 6 h (Audinot
et al., 2009). The orexigenic effect of proMCH (131–165), which
is more potent than MCH in stimulating feeding, was blocked
for 2 h by 50 nmol/kg of S38151 administered ICV (Maulon-
Feraille et al., 2002; Della-Zuana et al., 2012). Once daily ICV
injections of 20 nmol/kg of S38151 into male Zucker fa/fa rats,
reduced food intake, water intake, motility, and body weight
(Della-Zuana et al., 2012). A single injection of 20µmol/kg of
S38151 intraperitoneally (i.p.), reduced cumulative food intake in
Zucker fa/fa rats for 24 h (Della-Zuana et al., 2012). S38151 was
administered i.p. at 30 mg/kg for 5 days into two mouse models
of obesity, female ob/ob and female C57BL/6J DIO mice, result-
ing in reductions in body weight and cumulative food intake. The
S38151 effects on energy homeostasis were MCH1R based, since
no changes in food intake or body weight were observed after
5 days of i.p. injection into female Mchr1 KO mice (Della-Zuana
et al., 2012).
Studies with non-peptide MCHR1 antagonists
The overwhelming set of genetic and physiologic data
demonstrating that MCHR1 modulates energy homeostasis
attracted the interest of a many medicinal chemistry groups who
have synthesized numerous structurally distinct MCHR1 antag-
onists (see a recent review by Cheon, 2012). In all, 23 different
companies have published more than 100 medicinal chemistry
papers and patents describing attempts to optimize MCHR1
antagonist hit compounds toward drug candidates (see the recent
review of the patent literature by Johansson, 2011). Many of the
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Table 2 | Acute effects of non-peptide MCH1R antagonists on food intake.
Feeding model* Time of measurement Reference
2 h 4, 5, or 6 h 24 h
MCH-INDUCED HYPERPHAGIA IN RAT
Male Sprague-Dawley −90% Takekawa et al. (2002)
Male Sprague-Dawley −72% Moriya et al. (2009)
Male Sprague-Dawley −75% −75% Nagasaki et al. (2009)
Male Wistar −70% Borowsky et al. (2002)
FASTING-INDUCED FEEDING
Male Wistar rats −35% −30% −25% Huang et al. (2005)
Mice (strain and gender unknown) −80% −40% Balavoine et al. (2007)
DIO male C57BL/6NCrl:BR mice −35% −32% −22% McBriar et al. (2006)
DIO mice (strain and gender unknown) −17% −14% Palani et al. (2005)
DIO mice (strain and gender unknown) −12% −20% −9% Sasikumar et al. (2006)
SPONTANEOUS FEEDING
Male Sprague-Dawley rats −30% Kamata et al. (2011)
Female KKAy mice −63% Kamata et al. (2011)
DIO C57BL/6J mice (gender unknown) −19% Haga et al. (2011)
DIO mice (strain and gender unknown) −21% Xu et al. (2006)
DIO male F344/Jcl rats −30% Kasai et al. (2012)
DIO male F344/Jcl rats −28% Kasai et al. (2011)
DIO male Sprague-Dawley rats −31% Kowalski and Sasikumar (2007)
Male Sprague-Dawley rats, ingestion of condensed milk# −45% Borowsky et al. (2002)
*Data shown for the most potent analog in the cited reference at the highest dose tested.
#Measured at 20min.
resulting optimized lead compounds, representing a diverse set
of non-peptide MCHR1 antagonists, have been evaluated in vivo.
Non-peptide MCHR1 antagonists are effective in different mod-
els of acute food intake in a variety of different rodent strains
(Table 2) (Borowsky et al., 2002; Takekawa et al., 2002; Huang
et al., 2005; Palani et al., 2005; McBriar et al., 2006; Sasikumar
et al., 2006; Xu et al., 2006; Balavoine et al., 2007; Kowalski and
Sasikumar, 2007; Moriya et al., 2009; Nagasaki et al., 2009; Haga
et al., 2011; Kamata et al., 2011; Kasai et al., 2011, 2012). In general,
MCHR1 antagonists potently block up to 75% of MCH-induced
food intake (Borowsky et al., 2002; Takekawa et al., 2002; Moriya
et al., 2009; Nagasaki et al., 2009), but they have more mod-
est effects on reducing fasting-induced feeding and spontaneous
feeding.
Multiple MCHR1 antagonists have also shown dose-dependent
and sustained efficacy in chronic models of obesity (Kym et al.,
2005; Souers et al., 2005a,b, 2007; Vasudevan et al., 2005a,b; Car-
penter et al., 2006; Hertzog et al., 2006; Tavares et al., 2006a,b;
Mendez-Andino and Wos, 2007; Mendez-Andino et al., 2007;
Gehlert et al., 2009; Ito et al., 2009; Semple et al., 2009; Suzuki
et al., 2009; Hadden et al., 2010; Mihalic et al., 2012; Sasmal et al.,
2012a,b). At the highest dose tested in DIO mice, ranging from
10 to 100 mpk, weight loss ranged from 5% at 5 days to 33% at
238 days (Ito et al., 2009; Mihalic et al., 2012). In several cases,
weight loss was shown to be primarily due to the loss of fat mass
(Souers et al., 2005a,b, 2007; Vasudevan et al., 2005a; Mendez-
Andino et al., 2007). The mechanism of weight loss appears to
involve a combination of reduced food intake, which was observed
in six studies (Table 3), and increased energy expenditure with no
increase in activity (Kowalski et al., 2006; Gehlert et al., 2009).
As shown above with peptides, and in Tables 2 and 3 with non-
peptide compounds, many different MCHR1 antagonists have
demonstrated modest to robust efficacy in a variety of rodent
obesity models, suggesting that MCHR1 antagonists may have
potential for treating human obesity. One caveat for the data is
that in most cases, the antagonists have not demonstrated the
ability to induce weight loss through an MCHR1-specific mode
of action, since efficacy in Mchr1 KO mice has not been eval-
uated. In fact, in one report of robust weight loss, the authors
caution that some weight loss at the highest dose tested maybe
due to non-specific mechanisms, since the compound resulted
in high brain levels, 6.46µg/g (Kym et al., 2005). However, in
four reports, the MCHR1-specific efficacy of antagonists was con-
firmed, since the antagonists lacked efficacy in DIO Mchr1 KO
mice, but they showed body-weight loss in DIO wild-type mice
(Gehlert et al., 2009; Della-Zuana et al., 2012; Mashiko et al.,
2005; Mihalic et al., 2012). Further support for an MCHR1 mech-
anism based-weight loss has been reported for three compounds,
for which efficacy was correlated with brain MCHR1 receptor
occupancy (Hervieu et al., 2003; Kowalski et al., 2006; Ito et al.,
2009).
Studies with MCHR2 antagonists
The absence of the Mchr2 in rodents has limited the interest in
developing MCHR2-selective compounds. Only one paper has
disclosed a potent MCHR2-selective non-peptide small-molecule
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Table 3 | Chronic effects of non-peptide MCH1R antagonists in rodents.
Rodent model of energy homeostasis*
Reduced food intake
vs. vehicle (%)
Time (days) Reference
REDUCED CUMULATIVE FOOD INTAKE IN MICE
Male DIO C57BL/6J 16 5 Ito et al. (2009)
DIO (strain and gender unknown) 11 10 Mendez-Andino et al. (2007)
DIO (strain and gender unknown) 37 13 Kym et al. (2005)
DIO (strain and gender unknown) 13 14 Souers et al. (2005b)
Male DIO C57BL/6NCrl:BR 18 28 Kowalski et al. (2006)
REDUCED CUMULATIVE FOOD INTAKE IN RATS
DIO Long Evans (gender unknown) 16 14 Gehlert et al. (2009)
Weight loss vs.
vehicle (%)
Time (days) Reference
REDUCED BODY WEIGHT IN MICE
DIO C57BL/6J male 5 5 Ito et al. (2009)
DIO C57BL/6J male 6 5 Surman et al. (2010)
DIO C57BL/6J male 6 6 Hadden et al. (2010)
DIO (strain and gender unknown) 8 7 Mendez-Andino and Wos (2007)
DIO (strain and gender unknown) 5 10 Mendez-Andino et al. (2007)
DIO AKR/J (gender unknown) 13 12 Hertzog et al. (2006)
DIO (strain and gender unknown) 18 13 Kym et al. (2005)
DIO C57BL/6J male 8 13 Suzuki et al. (2009)
DIO C57BL/6J (gender unknown) 6 14 Vasudevan et al. (2005b)
DIO C57BL/6J (gender unknown) 12 14 Sasmal et al. (2012a)
DIO C57BL/6J (gender unknown) 13 14 Sasmal et al. (2012b)
DIO (strain and gender unknown) 7 14 Souers et al. (2007)
DIO (strain and gender unknown) 23 14 Vasudevan et al. (2005a)
DIO (strain and gender unknown) 15 14 Souers et al. (2005a)
DIO (strain and gender unknown) 17 14 Souers et al. (2005b)
DIO AKR/J (gender unknown) 10 15 Carpenter et al. (2006)
DIO AKR/J (gender unknown) 10 21 Tavares et al. (2006b)
DIO AKR/J (gender unknown) 15 26 Tavares et al. (2006a)
DIO (strain and gender unknown) 31 28 Kym et al. (2005)
DIO C57BL/6NCrl:BR male 16 28 Kowalski et al. (2006)
DIO C57BL/6J (gender unknown) 9 137 Mihalic et al. (2012)
DIO female (strain unknown) 33 238 Mihalic et al. (2012)
REDUCED BODY WEIGHT IN RATS
DIO Long Evans (gender unknown) 15 14 Gehlert et al. (2009)
DIO Sprague-Dawley male 15 14 Dyck et al. (2006)
DIO Wistar female 17 28 Semple et al. (2009)
*Data shown for the most potent analog in the cited reference at the highest dose tested.
antagonist (Chen et al., 2012). Compound 38 is a potent (Ki 13
nM) and selective MCHR2 antagonist with good oral bioavail-
ability and pharmacokinetics suitable for in vivo studies (Chen
et al., 2012). However, no in vivo data have been reported with this
compound.
CLINICAL STUDIES WITH MCHR1 ANTAGONISTS
The intense interest in MCHR1 antagonists has resulted in more
than 80 publications and 100 patent applications describing vari-
ous unique antagonists (Johansson, 2011). Five compounds have
reached testing in human subjects, but none has proceeded into
advanced Phase II studies to rigorously test their efficacy in causing
chronic weight loss (Figure 2). A major issue with many lead com-
pounds is increased cardiovascular risk due to high-affinity hERG
binding and drug-induced QTc prolongation (Mendez-Andino
and Wos, 2007).
The Amgen MCHR1 antagonist AMG 076 entered Phase I safety
and tolerability testing in 2004, but there have been no subsequent
reports of its status since 2005. GlaxoSmithKline MCHR1 antag-
onist GW-856464 also entered Phase I studies in 2004 (Cheon,
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FIGURE 2 | Structures of the five MCHR1 antagonists that have been evaluated in Phase I safety and tolerability studies.
2012). However, on August 24, 2010, Carmen Drahl reported via
Twitter that “low bioavailability precluded further development.”
NGD-4715 is a selective MCHR1 antagonist developed by Neu-
rogen. In a May 2, 2007 press release, Neurogen announced that
NGD-4715 was safe and well-tolerated in a Phase I clinical trial.
Neurogen was acquired by Ligand Pharmaceuticals in 2009; as of
February 22, 2013, the Wikipedia entry for NGD-4715 quotes an
e-mail from Ligand that there are “no plans for further devel-
opment on the compound.” In a May 31, 2011 press release,
AMRI announced that its MCHR1 antagonist, ALB-127158(a),
was well-tolerated in a Phase I single ascending-dose study and
14-day multiple ascending-dose safety and tolerability study. An
encouraging result reported by some subjects was loss of appetite.
Despite the reported tolerability and suggestion of efficacy, in a
subsequent press release dated October 4, 2011, AMRI announced
that development was terminated before the initiation of Phase II
studies.
Bristol–Myers Squibb (BMS) conducted the longest clinical
trial with an MCHR1 antagonist. As of February 22, 2013, the BMS
website indicates BMS-830216 was evaluated in a 28-day Phase I
study to assess the safety, tolerability, and effect on body weight and
other obesity-related factors of different doses of BMS-830216.
A summary of the clinical results with BMS-830216 is avail-
able on the NIH website (http://www.ncats.nih.gov/files/BMS-
830216.pdf), which indicates that BMS-830216 is a prodrug of
the antagonist BMS-819881 and a potent (K i= 10 nM) and selec-
tive MCHR1 antagonist. BMS-830216 was generally safe and
well-tolerated at all doses in the Phase I study for up to 28 days.
However, no indications of weight loss or reduced food intake
were observed, and the compound did not proceed to Phase II
studies.
FUTURE PROSPECTS
A rich literature of rodent genetics and rodent pharmacology
demonstrates a significant role for MCH, acting via the MCHR1
within the hypothalamus, in maintaining energy homeostasis.
This knowledge has stimulated more than 20 companies to seek
MCHR1 selective compounds for the treatment of obesity. Five
companies are known to have succeeded in identifying develop-
ment candidates that proceeded through preclinical safety studies
and enabled Phase I clinical safety and tolerability testing. Three
of the compounds, NGD-4715, ALB-127158(a), and BMS-830216
(Figure 1), were found generally safe and well-tolerated in the
Phase I studies. However, BMS-830216, which was tested for
28 days in obese subjects, failed to show any significant weight
loss efficacy. No compounds have proceeded into Phase II studies
in which chronic efficacy could be evaluated.
After almost 15 years of research, studies have failed to detect
anti-obesity efficacy with MCHR1 antagonists in the clinic. There
are multiple reasons that might account for this disconnect
between rodent and human studies. First, compounds tested in the
clinic may not have had the appropriate properties to sufficiently
block the MCHR1 receptor and achieve an effect of energy bal-
ance. For instance, the MCHR1 antagonists may not have reached
the hypothalamic sites of MCH action. Since there have been no
reported studies measuring the level of receptor occupancy of the
clinical compounds, it is possible that the compounds failed to
sufficiently penetrate the brain: blood barrier resulting in low
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and insufficient receptor occupancy. Second, studies utilizing a
positron emission tomography (PET) ligand demonstrated that
an NPY5R antagonist must achieve >90% receptor occupancy
sustained over 24 h to cause weight loss (Erondu et al., 2006). Sim-
ilarly, in DIO mouse studies, maximum weight loss was observed
only when an MCHR1 antagonist blocked >90% of the MCHR1
receptors for 24 h (unpublished data by the author). Clearly, a
MCHR1 PET ligand could guide compound dose selection to
assure 24 h of high receptor blockade (Erondu et al., 2006; Philippe
et al., 2012). Third, since humans also express MCHR2 in the
hypothalamus (Sailer et al., 2001), MCH signaling in humans may
involve both MCHR1 and MCHR2, such that blockade of the
MCHR1 alone may not be sufficient to achieve efficacy in obe-
sity. Fourth, the role of MCH in human energy homeostasis may
not be as significant as its role in rodents, consequently, block-
ade of MCHR1 would be inherently ineffective as a treatment for
obesity.
In the author’s opinion, there is, at best, only a modest probabil-
ity that an MCHR1 antagonist will be developed as a treatment for
obesity. Following the failure of five Phase I compounds to progress
to Phase II efficacy studies, the enthusiasm for MCHR1 antagonists
has clearly dimmed. Moreover, after more than a decade of drug
discovery effort by more than 20 companies, there are currently
no known MCHR1 antagonists in the clinic for obesity. Should
any company continue to seek MCHR1 antagonists, the author
suggests that they should proceed only with the aid of a PET lig-
and, perhaps [11C]SNAP-7941, or another on-target biomarker
to assess receptor occupancy (Philippe et al., 2012). Companies
might also consider focusing their chemistry efforts on identifying
a dual MCHR1 and MCHR2 antagonist, to assure that all MCH-
mediated signaling involved in energy homeostasis is effectively
blocked. Finally, an effective MCH antagonist therapy for obesity
must not only achieve meaningful weight loss, but it must also
be well-tolerated. Although not discussed in this review, there is
significant rodent genetic and pharmacologic data indicating that
MCH participates in other CNS behaviors (Saito and Nagasaki,
2008; Yumiko and Nagasaki, 2008; Antal-Zimanyi and Khawaja,
2009; Torterolo et al., 2009; Chung et al., 2011). In particular, stud-
ies in multiple rodent models suggest blockade of MCH signaling
may be anxiolytic (Antal-Zimanyi and Khawaja, 2009; Chung et al.,
2011). Tolerability may be a substantial hurdle for an effective
MCH receptor antagonist to overcome.
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